MADRIGAL PHARMACEUTICALS, INC. Stock Issued During Period, Shares, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MADRIGAL PHARMACEUTICALS, INC. stock issued during period, shares, new issues for the quarter ending 2021-09-30 was 0.00 shares.
- MADRIGAL PHARMACEUTICALS, INC. stock issued during period, shares, new issues for the quarter ending 2021-06-30 was 0.00 shares.
- MADRIGAL PHARMACEUTICALS, INC. stock issued during period, shares, new issues for the quarter ending 2021-03-31 was 1.09M shares, a 2644.78% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. stock issued during period, shares, new issues for the quarter ending 2020-12-31 was 0.00 shares.
- MADRIGAL PHARMACEUTICALS, INC. stock issued during period, shares, new issues for fiscal 2020 was 39.61K shares.
| Period end | Stock Issued During Period, Shares, New Issues 3 month | Stock Issued During Period, Shares, New Issues 12 month |
|---|---|---|
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 1.09M shares derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 1.09M shares derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | 1.09M shares 10-Q · filed 2022-05-09 | 1.09M shares derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | 39.61K shares 10-K/A · filed 2023-03-03 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | |
| 2020-03-31 | 39.61K shares 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |